- Home
- UOKA vs EXEL Comparison
UOKA vs EXEL Comparison
Compare UOKA & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UOKA
- EXEL
- Stock Information
- Founded
- UOKA 2002
- EXEL 1994
- Country
- UOKA United Kingdom
- EXEL United States
- Employees
- UOKA N/A
- EXEL N/A
- Industry
- UOKA
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UOKA
- EXEL Health Care
- Exchange
- UOKA NYSE
- EXEL Nasdaq
- Market Cap
- UOKA 2.7M
- EXEL 11.3B
- IPO Year
- UOKA N/A
- EXEL 2000
- Fundamental
- Price
- UOKA $2.57
- EXEL $46.00
- Analyst Decision
- UOKA
- EXEL Buy
- Analyst Count
- UOKA 0
- EXEL 18
- Target Price
- UOKA N/A
- EXEL $43.00
- AVG Volume (30 Days)
- UOKA 54.2K
- EXEL 3.6M
- Earning Date
- UOKA 08-16-2025
- EXEL 08-05-2025
- Dividend Yield
- UOKA N/A
- EXEL N/A
- EPS Growth
- UOKA N/A
- EXEL 237.58
- EPS
- UOKA N/A
- EXEL 2.20
- Revenue
- UOKA $48,375.00
- EXEL $2,298,922,000.00
- Revenue This Year
- UOKA N/A
- EXEL $9.37
- Revenue Next Year
- UOKA N/A
- EXEL $11.05
- P/E Ratio
- UOKA N/A
- EXEL $20.94
- Revenue Growth
- UOKA N/A
- EXEL 24.49
- 52 Week Low
- UOKA $1.98
- EXEL $21.82
- 52 Week High
- UOKA $42.50
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- UOKA N/A
- EXEL 59.21
- Support Level
- UOKA N/A
- EXEL $43.32
- Resistance Level
- UOKA N/A
- EXEL $44.48
- Average True Range (ATR)
- UOKA 0.00
- EXEL 1.54
- MACD
- UOKA 0.00
- EXEL 0.12
- Stochastic Oscillator
- UOKA 0.00
- EXEL 47.90
About UOKA MDJM LTD
MDJM Ltd is engaged in providing real estate agency services to its real estate developer clients, and provides, on an as-needed basis, real estate consulting services and independent training services. The company generates all of its revenue from Hotel income. The company derives a majority of its revenue from the United Kingdom.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.